SCHEMBL13879480

SCHEMBL13879480

CCOC(=O)CCC1NC(=O)N(c2ccc(Cl)cc2)C1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 1/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 3/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSP90AA1 P07900 1/20 0.39
PKM P14618 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879442 0.87 ALOX15 (0.43) MAPTALDH1A1KDM4EMEN1HPGD
SCHEMBL13879400 0.78 GRM2 (0.44) CDC25BMAPTALDH1A1KDM4ERAB9A
SCHEMBL13879377 0.76 PKM (0.41) ALDH1A1KDM4EHPGDKMT2ANPSR1
SCHEMBL11612591 0.74 KMT2A (0.48) MAPTALDH1A1RAB9AHTTMEN1
SCHEMBL10743922 0.73 LARS1 (0.36) MAPTALDH1A1KDM4ENPC1RAB9A
SCHEMBL8575699 0.72 GAA (0.43) MAPTALDH1A1KDM4EHPGDKMT2A
SCHEMBL13879466 0.71 TAS2R8 (0.39)
SCHEMBL1074900 0.71 ALDH1A1 (0.51) CDC25BMAPTALDH1A1KDM4ENPC1
SCHEMBL10739194 0.71 CA9 (0.48) MAPTALDH1A1NPC1RAB9AMEN1
SCHEMBL10739202 0.71 CA9 (0.48) MAPTALDH1A1NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 CDC25B 531/4885MAPT 4203/4885ALDH1A1 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.